The study, led by D. Cyril D'Souza, M.D., associate professor of psychiatry at Yale School of Medicine, set out to explore a long-known association between cannabis and psychosis.

"Just as studies with amphetamines and ketamine advanced the notion that brain systems utilizing the chemical messengers dopamine and NMDA receptors may be involved in the pathophysiology in schizophrenia, this study provides some tantalizing support for the hypotheses that the brain-receptor system that cannabis acts on may be involved in the pathophysiology of schizophrenia," said D'Souza. "Clearly, further work is needed to test this hypothesis."

For the study, researchers administered varying doses of delta-9-THC to participants who were screened for any vulnerability to schizophrenia. Some participants showed symptoms commonly associated with schizophrenia, which lasted about a half hour to one hour after being given THC. Symptoms included suspiciousness, unusual thoughts, paranoia, thought disorder, blunted affect, reduced spontaneity, reduced interaction with the interviewer, and problems with memory and attention.

The study was published June 2 on the website of the journal Neuropsychopharmacology.

COMMENTS ON THIS ARTICLE:

Your Turn! Post a public comment (read guidelines):

Name:
Comment: (limit 200 words)
Enter this word (help):	Change

GUIDELINES: 
To keep this feature useful for all, please:

1. Keep it clean, courteous, and on-topic. Comments are meant for thoughtful discussion of the article published above.
   
   
2. Do not post promotional links to organizations, products or services, or personal requests for assistance (get help).
   
   
3. Proof your comments carefully, use good spelling and punctuation, and don't use ALL CAPS. Comments are published immediately and cannot be edited.

Deceptive, slanderous and commercially-motivated posts are prohibited. We reserve the right to remove comments not conforming to these guidelines. (Report a comment).

Have questions or feedback? Contact us.